[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"trial:NCT06925685":3,"trial-entities:NCT06925685":70,"trial-summary:NCT06925685":75},{"id":4,"nct_id":4,"org_study_id":5,"brief_title":6,"official_title":7,"overall_status":8,"completion_date":9,"status_verified_date":10,"last_update_date":11,"start_date":12,"sponsor_name":13,"lead_sponsor_class":14,"has_dmc":15,"brief_summary":16,"detailed_description":17,"conditions":18,"keywords":21,"study_type":25,"primary_purpose":17,"phases":26,"enrollment_info":27,"interventions":30,"primary_outcomes":31,"secondary_outcomes":40,"sex":41,"minimum_age":17,"maximum_age":17,"healthy_volunteers":15,"eligibility_criteria":42,"std_ages":48,"locations":52,"central_contacts":62,"overall_officials":63,"references":68,"see_also_links":69},"NCT06925685","ALLO-LTFU-101","Follow-Up for Study Participants Treated With an Allogeneic CAR T-Cell Product","Long Term Follow up Study for Participants Treated With an Allogeneic CAR T-Cell Product in a Prior Clinical Study","ENROLLING_BY_INVITATION","2039-01","2025-04","2025-04-13","2025-01-31","Allogene Therapeutics","INDUSTRY",false,"An observational, long-term follow up (LTFU) study of participants who received an allogeneic CAR T product in a prior clinical study. Participants will be followed for 15 years after their last infusion of an allogenic CAR T cell product.",null,[19,20],"Hematologic Malignancies","Solid Tumors",[22,23,24],"CAR T","Allogeneic CAR T","long term follow up","OBSERVATIONAL",[],{"count":28,"type":29},50,"ESTIMATED",[],[32,35,38],{"measure":33,"timeFrame":34},"Incidence of delayed adverse events potentially related to allogeneic CAR T-cell product and allogeneic CAR T-cell product-related SAEs","Up to 15 years post treatment with allogeneic CAR T-cell product",{"measure":36,"timeFrame":37},"Overall survival (OS)","Up to 15 years post treatment with allogeneic CAR T cell product",{"measure":39,"timeFrame":37},"Presence of replication competent lentivirus (RCL) in blood",[],"ALL",{"inclusion":43,"exclusion":45,"raw_text":47},[44],"Received an allogenic CAR T-cell product infusion to treat an oncologic condition in a previous Allogene or Servier sponsored clinical study",[46],"Less than 12 months of follow up after the last allogeneic CAR T-cell product, unless approved by the Allogene Medical Monitor","Inclusion Criteria:\n\n* Received an allogenic CAR T-cell product infusion to treat an oncologic condition in a previous Allogene or Servier sponsored clinical study\n\nExclusion Criteria:\n\n* Less than 12 months of follow up after the last allogeneic CAR T-cell product, unless approved by the Allogene Medical Monitor",[49,50,51],"CHILD","ADULT","OLDER_ADULT",[53],{"facility":54,"city":55,"state":56,"zip":57,"country":58,"geoPoint":59},"Circuit Clinical","Buffalo","New York","14203","United States",{"lat":60,"lon":61},42.88645,-78.87837,[],[64],{"name":65,"affiliation":66,"role":67},"Allogene Study Director","Allogene Therapeutics, Inc.","STUDY_DIRECTOR",[],[],{"nct_id":4,"conditions":71,"biomarkers":74},[72,73],"Hematologic Neoplasm","Solid Neoplasm",[],{"nct_id":4,"found":15,"summary":17,"prompt_version":17}]